Tocilizumab for COVID-19: The Return (RECOVERY Group) Journal Club-ish

Analyzing the RECOVERY analysis of Tocilizumab in COVID-19 patients. Is it time to put it back into the arsenal after several failed trials? Hat tip to the authors. Show Notes: www.eddyjoemd.com/tocilizumab-recovery Receive a FREE audiobook (TWO for Amazon Prime members) with your FREE 30-day trial by using my link for Audible: CLICK HERE! You will be reminded when your trial is ending, by the way. 😉 Although great care has been taken to ensure that the information in this podcast are accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Website: www.eddyjoemd.com Instagram: www.instagram.com/eddyjoemd Twitter: www.twitter.com/eddyjoemd Facebook: www.facebook.com/eddyjoemd Podcast: https://anchor.fm/eddyjoemd My Amazon store for resources you may find helpful: www.amazon.com/shop/eddyjoemd Citation: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trialPeter W Horby, Mark Campbell, Natalie Staplin, Enti Spata, Jonathan R Emberson, Guilherme Pessoa-Amorim, Leon Peto, Christopher E Brightling, Rahuldeb Sarkar, Koshy Thomas, Vandana Jeebun, Abdul Ashish, Redmond Tully, David Chadwick, Muhammad Sharafat, Richard Stewart, Banu Rudran, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Furst, Thomas Jaki, Katie Jeffery, EdmundJuszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, GuyThwaites, Marion Mafham, Richard Haynes, Martin J LandraymedRxiv 2021.02.11.21249258; doi:https://doi.org/10.1101/2021.02.11.21249258